IDH1突变胶质瘤对HDAC抑制剂帕比司他优先敏感
研究比较IDH1野生型与突变型患者来源胶质瘤细胞系对FDA批准的HDAC抑制剂帕比司他的敏感性。IDH1突变胶质瘤细胞对帕比司他的细胞毒和抗增殖作用显著更敏感,且组蛋白H3K14、H3K18、H3K27乙酰化增加更明显,丙戊酸也显示类似效果。提示IDH1突变胶质瘤可能优先对HDAC抑制剂敏感。
要点
- IDH1突变胶质瘤细胞对帕比司他细胞毒和抗增殖作用更敏感
- 帕比司他在IDH1突变细胞中引起H3K14、H3K18、H3K27乙酰化更大增加
- 丙戊酸对IDH1突变胶质瘤细胞也更有效
核心结论
- IDH1突变胶质瘤可能优先对HDAC抑制剂敏感,其机制与组蛋白乙酰化积累增强相关。
研究设计与样本
- 使用6株患者来源胶质瘤细胞系,其中IDH1野生型3株、IDH1突变型3株,给予FDA批准的HDAC抑制剂帕比司他处理。
- 通过流式细胞术检测细胞毒性和增殖,采用免疫印迹和/或ELISA评估组蛋白修饰和细胞信号通路。
主要发现
- IDH1突变胶质瘤细胞中与HDAC活性相关的基因显著上调。
- 与IDH1野生型胶质瘤细胞相比,IDH1突变胶质瘤细胞对帕比司他的细胞毒和抗增殖作用显著更敏感。
- 帕比司他在IDH1突变胶质瘤细胞中引起组蛋白H3K14、H3K18和H3K27乙酰化更大增加。
- 另一种HDAC抑制剂丙戊酸对IDH1突变胶质瘤细胞也更有效。
临床怎么用
- 提示对IDH1突变胶质瘤患者可进一步探索HDAC抑制剂治疗。
局限性
- 研究仅基于6株体外培养的患者来源胶质瘤细胞系,尚未在体内或临床中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A large subset of diffusely infiltrative gliomas contains a gain-of-function mutation in isocitrate dehydrogenase 1 or 2 (IDH1/2mut) which produces 2-hydroxglutarate, an inhibitor of α-ketoglutarate-dependent DNA demethylases, thereby inducing widespread DNA and histone methylation. Because histone deacetylase (HDAC) enzymes are localized to methylated chromatin via methyl-binding domain proteins, IDH1/2mut gliomas may be more dependent on HDAC activity, and therefore may be more sensitive to HDAC inhibitors. METHODS: Six cultured patient-derived glioma cell lines, IDH1wt (n = 3) and IDH1mut (n = 3), were treated with an FDA-approved HDAC inhibitor, panobinostat. Cellular cytotoxicity and proliferation assays were conducted by flow cytometry. Histone modifications and cell signaling pathways were assessed using immunoblot and/or ELISA. RESULTS: IDH1mut gliomas exhibited marked upregulation of genes associated with the HDAC activity. Glioma cell cultures bearing IDH1mut were significantly more sensitive to the cytotoxic and antiproliferative effects of panobinostat, compared to IDH1wt glioma cells. Panobinostat caused a greater increase in acetylation of the histone residues H3K14, H3K18, and H3K27 in IDH1mut glioma cells. Another HDAC inhibitor, valproic acid, was also more effective against IDH1mut glioma cells. CONCLUSION: These data suggest that IDH1mut gliomas may be preferentially sensitive to HDAC inhibitors. Further, IDH1mut glioma cultures showed enhanced accumulation of acetylated histone residues in response to panobinostat treatment, suggesting a direct epigenetic mechanism for this sensitivity. This provides a rationale for further exploration of HDAC inhibitors against IDH1mut gliomas.
引用
- Sears TK, Horbinski CM, Woolard KD, et al. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat. J Neurooncol. 2021. PMID: 34424450. doi:10.1007/s11060-021-03829-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。